Background and aims: Activation of protease-activated receptor-2 (PAR-2) may stimulate various events of importance in inflammatory processes, including release of inflammatory mast cell mediators. PAR-2 is frequently up-regulated during inflammatory conditions, but it is not known if the expression is altered in Crohn's disease. The aim of the present study was to investigate the ileal mucosal PAR-2 expression in Crohn's ileitis, with particular emphasis on the expression in ileal mucosal mast cells. Methods: Surgical specimens from the distal ileum were collected from patients with Crohn's ileitis and patients with colonic cancer as controls. The overall expression of PAR-2 was investigated by Western blot, and the presence of PAR-2 expressing mucosal mast cells by immunohistochemistry and cell counting. The effect of tumor necrosis factor-α (TNF-α) on the PAR-2 expression in a human mast cell line (HMC-1) was investigated by RT-PCR and immunocytochemistry. Results: In Crohn's specimens, the fraction of PAR-2-expressing mucosal mast cells was increased about 2.5 times (P b 0.001; n = 14) compared with specimens from control patients (n = 6). No difference was found between inflamed (n = 6) and uninflamed Crohn's specimens (P N 0.05; n = 8). Exposure to TNF-α for 48 h up-regulated PAR-2 mRNA and protein expression in the HMC-1 cell line. Conclusion: PAR-2 is up-regulated on ileal mucosal mast cells in Crohn's ileitis, possibly due to the action of inflammatory cytokines, such as TNF-α. This may contribute to perpetuating the inflammatory process in the intestinal mucosa in Crohn's ileitis.
Introduction
Protease-activated receptor-2 (PAR-2) is a G-protein coupled receptor that is activated by proteolytic cleavage by specific serine proteases, such as trypsin and mast cell tryptase. 1 PAR-2 is widely distributed among different cell types throughout the human intestine, [2] [3] [4] [5] [6] [7] [8] [9] and is thought to modulate various intestinal functions in both health and disease. 10 In particular, increasing clinical and experimental evidence shows that PAR-2 activation is of importance in inflammatory processes, 1 also within the gastrointestinal tract. 7, [10] [11] [12] [13] And PAR-2 expression is frequently up-regulated during inflammatory conditions. 12, [14] [15] [16] [17] [18] [19] [20] [21] [22] [23] [24] There are, however, no previous published reports on the expression of PAR-2 in the intestinal mucosa of Crohn's disease.
Mast cells are considered to be involved in various aspects of the pathogenesis of Crohn's disease, [25] [26] [27] such as stricture formation, 28 and may also play a role in disruption of the intestinal epithelial barrier. 13 Upon activation, mast cells are known to release large amounts of various mediators of potential relevance in inflammatory conditions, [25] [26] [27] including tryptase, 29 which may act as a paracrine and/or autocrine activator of PAR-2 receptors, 7, 25, 30 and histamine. 25, [30] [31] [32] Moreover, we have previously demonstrated that most of the TNF-α-expressing cells in the ileal mucosa in Crohn's disease are mast cells. 33 Although several lines of evidence point to the possibility that PAR-2 activation of mast cells may play a role in the pathophysiology of Crohn's disease, it is still unknown to what extent ileal mucosal mast cells express PAR-2, and if this expression is altered in Crohn's ileitis. The principle aim of the present study was therefore to investigate PAR-2 expression in ileal mucosa, in particular mucosal mast cells, in patients with Crohn's ileitis and in control patients. Moreover the effects of TNF-α on PAR-2 expression were studied in a human mast cell line.
Materials and methods

Subjects
Full-thickness sections of ileal wall and/or mucosa were collected from 26 patients operated upon at the University Hospital of Linköping. Fifteen of the patients were operated on for Crohn's ileitis and 11 for colonic cancer, serving as controls. Eleven of the 15 Crohn's patients were taking medication, including steroids (prednisolone), azathioprine and mesalazine. Sampled specimens were submitted to the Department of Pathology for routine pathological evaluation, and specimens from Crohn's patients were considered as being uninflamed only if no signs of microscopic inflammation were observed. Ten out of 11 inflamed specimens were macroscopically inflamed. From five of the Crohn's patients, samples were taken from both uninflamed and inflamed areas. The specimens were analyzed for PAR-2 expression by western blot and/or immunohistochemistry. Details about the sampled ileal specimens and which analysis was performed are given in Table 1 . The study was approved by the Regional Ethical Review Board in Linköping, and carried out in accordance with the Declaration of Helsinki.
Antibodies and reagents
Mouse monoclonal antibody to human PAR-2 (FITC conjugated, subclass IgG 2a ), goat polyclonal antibody to human PAR-2 (N-19), and goat polyclonal antibody to human Actin (I-19) was obtained from Santa Cruz Biotechnology, Inc (Santa Cruz, CA, USA). Mouse monoclonal antibody to human mast cell tryptase (clone AA1, subclass IgG 1κ ), normal rabbit serum, Negative control mouse antibody IgG 2a , biotinylated F(ab′) 2 rabbit anti-mouse IgG and FITC conjugated streptavidin was obtained from DakoCytomation (Glostrup, Denmark). TRITC-conjugated F(ab′) 2 fragment rabbit antimouse IgG and HRP-conjugated rabbit anti-goat was obtained from Jackson ImmunoResearch Laboratories, Inc (West Grove, PA, USA). Vectashield ® mounting medium with propidium iodide was from Vector Laboratories, Inc (Burlingame, CA, USA). Heparin Leo 5000 IU/ml was bought from LEO Pharma A/S (Ballerup, Denmark). Precast trisglycine gels and nitrocellulose membrane from Invitrogen Life Technologies Ltd (Paisley, UK). ECL Plus Western blotting detection system and Hyperfilm ECL from GE Healthcare (Chalfont St Giles, UK). Iscoves modified Dulbecco's medium (IMDM) and foetal calf bovine serum (FCS) were from Gibco (Invitrogen Life Technologies Ltd, Paisley, UK).
Western blot
Human ileal tissue was homogenized in RIPA buffer containing PMSF (0.1 mg/ml), aprotinin (30 μl/ml) and sodium orthovanadate (1 mM). After centrifugation, total proteins 
RT-PCR
Hexamer-primed cDNA was generated (Omniscript reverse transcript RT Kit, Qiagen, Solna, Sweden) from 1 µg isolated total RNA (Ultraspec II RNA Isolation system, Nordic Biosite, Täby, Sweden) and amplified using PuRe Taq RTG PCR beads (GE Healthcare, Buckinghamshire, UK) and primers (Invitrogen Life Technologies Ltd, Paisley, UK) specific for human PAR-2 (forward, 5′-CCA TCC AAG GAA CCA ATA G-3′; reverse, 5′-CTG AGG CAG GTC ATG AAG-3′, product size 436 bp) 34 and for human 18 S (forward, 5′-ACG RAC CAG AGC GAA AGC AT-3′; reverse, 5′-GGA CAT CTA AGG GCA TCA CAG AC-3′, product size 531 bp). 35 Untranscribed total RNA was used as negative 
Immunohistochemistry
To evaluate the localization of PAR-2 expressing cells in the ileal bowel wall, tissue slides were fixed in acetone in −20°C for 5 min and then blocked with 50% normal rabbit serum for 1 h in room temperature. Prior application, to avoid interactions other than immunological, the anti-human mast cell tryptase antibody (1:200, 0.4 µg/ml) was pre-incubated with heparin 1000 IU/ml in PBS pH 6.0 as previously described. 36 After application the slides were incubated at 4°C for 16 h. Also, the secondary rabbit anti-mouse antibody (1:50, 10 µg/ml) was pre-incubated with heparin 1000 IU/ml in PBS pH 6.0 and then applied to the slides to incubate for 1 h at room temperature. The FITC-conjugated anti-human PAR-2 antibody (SAM 11; 1:50, 4 µg/ml) was incubated at 4°C for 16 h. Finally, the slides were mounted in Mowiol ® 4-88 and placed in the dark at 4°C until microscopic evaluation. As negative control to anti-PAR-2 antibody an irrelevant Negative control mouse antibody IgG 2a , biotin conjugated secondary antibody and FITC conjugated streptavidin was used. As negative control to the mast cell staining primary antibody was omitted.
Evaluation of immunohistochemistry and mast cell count
Sections were examined using NikonEclipse E600 Confocal Microscope (Nikon, Japan) and Nikon Confocal Microscope EZ-C1 Software version 2.0. The total number of ileal mucosal mast cells, and the PAR-2 + mast cells was counted at a magnification of ×600. At least 400 cells/patient were counted. The number of mast cells/mm 2 , and the number of PAR-2 + mast cells/mm 2 were evaluated. Additionally, the proportion of PAR-2 + mast cells was examined. Any mast cell showing immunological staining with the PAR-2 antibody was considered as being PAR-2 + , regardless of the labeling intensity.
Stimulation of PAR-2 expression in a human mast cell line
The human leukemia mast cell line HMC-1 (kind gift from Dr J.H. Butterfield, Mayo Clinic, Rochester, USA) was cultured in IMDM supplemented with 10% FCS, 1.2 mM α-thioglycerol, 100 µg/ml streptomycin and 100 U/ml penicillin. The cell line was maintained at 37°C in a humidified atmosphere of 5% CO 2 in air. Cells were seeded, at a number of 5 × 10 5 , and cultured for 48 h with TNF-α (25 ng/ml) and then analyzed for PAR-2 expression using immunocytochemistry.
Immunocytochemistry
Cultured HMC-1 cells, were washed, smeared on poly-Llysine coated glass slides and then allowed to air dry for at least 30 min.
Slides were fixed in 4% formaldehyde for 15 min at room temperature and then incubated with PBS containing 50% normal rabbit serum for 1 h. The samples were incubated with anti-human PAR-2 antibody (SAM-11; FITC 1:50, 4 µg/ml) for 16 h at 4°C. Slides were washed and mounted with Vectashield ® mounting medium with propidium iodide. As negative control to anti-PAR-2 antibody an irrelevant Negative control mouse antibody IgG 2a , biotin conjugated secondary antibody and FITC conjugated streptavidin was used.
Statistics
If not otherwise indicated, results are expressed as mean ± SEM. Comparative statistical analysis was made with Wilcoxon rank sum test (between groups), and with Wilcoxon signed rank test in the case of paired samples (inflamed versus non-inflamed specimens within the same patients), with p b 0.05 considered significant.
Results
No alteration in overall ileal PAR-2 expression in Crohn's ileitis
Considering the frequently observed up-regulation of PAR-2 in various inflammatory conditions, we first investigated the overall ileal mucosal expression of PAR-2. As seen in Fig. 1 , the overall expression of PAR-2 in ileal mucosal specimens from Crohn's patients was not significantly different from the expression in control patients, as assessed by Western blot analysis. For methodological reasons, however, only macroscopically uninflamed mucosa could be investigated from the Crohn's patients (it was not possible to properly separate the inflamed mucosa from the underlying tissues). In addition, therefore, we also investigated the PAR-2 expression in inflamed full-thickness ileal specimens from Crohn's patients. As seen in Fig. 2 , no difference in overall PAR-2 expression was found between full-thickness specimens from Crohn's patients and control patients.
Increased number and proportion of PAR-2 expressing mast cells in Crohn's ileitis
Since the high expression of PAR-2 in the human ileum 2, 3, 5 may mask alterations confined to specific cell types within the mucosa, and considering the proposed role of PAR-2 in Cells positively stained with the tryptase antibody were found in the ileal lamina propria of both Crohn's ileitis patients and control patients, and were considered as being mast cells. The total number of mast cells/mm 2 was increased in specimens from patients with Crohn's ileitis, compared to specimens from control patients (87.8 ± 10.9, n = 14, versus 48.3 ± 3.8, n = 6; P b 0.01; Fig. 3 ). No significant difference was found between inflamed and uninflamed Crohn's specimens (71.9 ± 5.6, n = 6 versus 96.5 ± 16.2, n = 8; P N 0.05; Fig. 3) .
A fraction of the mast cells in both control and Crohn's specimens were positive for the PAR-2 antibody. Mast cells Figure 3 Immunohistochemical analysis of the number of mast cells in ileal mucosal specimens. Control specimens (Ctrl; n = 6), uninflamed Crohn's ileitis specimens (CD ui ; n = 8), and inflamed Crohn's ileitis specimens (CD i ; n = 6). CD tot = CD ui + CD i ; n = 14. Immunostaining with tryptase antibody and cell counting were performed as described in Materials and methods. Data about patients and specimens are given in Table 1 were considered as being positive for PAR-2 regardless of labeling intensity, and no attempt was done to compare the labeling intensity between different specimens. However, mast cells in Crohn's specimens tended to be more intensely PAR-2 labeled than mast cells in control specimens. Typical immunohistochemical stainings of PAR-2 expressing mast cells showing various labeling intensity and mast cells negative for PAR-2, are shown in Fig. 4 . The total number of PAR-2 expressing mucosal mast cells/mm 2 was significantly higher in specimens from Crohn's disease patients, compared to controls (68.8 ± 10.1, n = 14, versus 14.1 ± 2.4, n = 6; P b 0.001; Fig. 5 ), with no difference between inflamed and uninflamed Crohn's mucosa (58.2 ± 4.1, n =6, versus 74.0±15.5, n = 8 respectively; P N 0.05; Fig. 5 ).
To examine if the increased number of PAR-2 expressing mucosal mast cells in Crohn's specimens was merely due to the increased mast cell number, the proportion of PAR-2 expressing mast cells was calculated. As seen in Fig. 6 , the proportion of PAR-2 positive mast cells was significantly higher in specimens of Crohn's ileitis (77.7 ± 3.9%, n = 14, versus 31.0 ± 7.2%, n = 6; P b 0.001). Again, no difference, was found between inflamed and uninflamed Crohn's mucosa (81.9 ± 5.8%, n = 6, versus 75.3 ± 5.2%, n = 8; P N 0.05; Fig. 6 ).
In pair-wise comparisons of macroscopically inflamed and microscopically uninflamed areas obtained from the same five Crohn's patients, no differences were found in total mast cell number/mm 2 (71.9 ± 5.6, versus 63.3 ± 8.1; P N 0.05), number of PAR-2 expressing mast cells/mm 2 (58.2 ± 4.1 versus 50.1 ± 6.4; P N 0.05), or proportion of PAR-2 expressing mast cells (81.9 ± 5.8%, versus 79.3 ± 1.6%; P N 0.05).
TNF-α up-regulates PAR-2 in a human mast cell line
Inflammatory cytokines are known to increase the PAR-2 expression in several cell types, 14, 23, [37] [38] [39] [40] [41] and might be responsible for our finding that PAR-2 was up-regulated on mucosal mast cells in Crohn's ileitis. Therefore, we next investigated if PAR-2 expression in human mast cells may be affected by TNF-α, an inflammatory cytokine of prime importance in the pathophysiology of Crohn's disease. 42, 43 The human leukemia mast cell line, HMC-1, showed a basal expression of PAR-2, as demonstrated with RT-PCR (Fig. 7 A) and immunocytochemistry (Fig. 7 B) . PAR-2 expression was significantly increased in cells incubated with 25 ng/ml TNF-α for 48 h (Fig. 7 A and 7 C) .
Discussion
Increasing evidence shows that PAR-2 may have a role in inflammatory processes, both in the gastrointestinal tract, 7, [10] [11] [12] [13] and at other locations. 1 PAR-2 is known to be up-regulated in various inflammatory conditions, 12,14-24 but to our knowledge, the present study is the first one addressing the expression of PAR-2 in Crohn's disease. Although mast cells of the human colon 7, 8 and small intestine 8 have been reported to express PAR-2, this is the first study specifically showing that human ileal mucosal mast cells do express this receptor. Moreover, our results suggest that PAR-2 is up-regulated in ileal mucosal mast cells in patients with Crohn's ileitis, but that this increase is too low to be detected as an increase in overall ileal PAR-2 expression by Western blot. Consequently, although PAR-2 is widely expressed among different cell types in the human intestine, 2, 3, 5 Crohn's ileitis seems to be associated with a an up-regulation of PAR-2 restricted to one or few specific cell types, such as mast cells. However, further immunohistochemical studies investigating the PAR-2 expression in various cell types of the Crohn's disease mucosa are needed to elucidate this issue. PAR-2 is increased in human neoplastic tissues, 44 and colorectal cancer has been reported to affect the distal small intestine by, for instance, lymphatic spread of cancer cells. 45 The ileal control specimens from colorectal cancer patients were, however, normal (no signs of inflammation or neoplastic transformation) on histopathological evaluation. Although, one cannot totally exclude the possibility that the PAR-2 expression was affected in these specimens, it is unlikely from the normal microscopy that upregulation of PAR-2 in the control specimens might have masked any differences in overall PAR-2 expression between controls and Crohn's disease specimens.
Our finding that the number of PAR-2-expressing mucosal mast cells was increased in Crohn's ileitis is in line with previous findings by Kim and colleagues, 7 reporting an increased number of PAR-2-expressing mucosal mast cells in ulcerative colitis. However, since the overall numbers of mucosal mast cells in controls and ulcerative colitis patients were not given in this report, 7 it is not possible to find out if the increased number of PAR-2 expressing mast cells in ulcerative colitis was due to an increased number of mucosal mast cells in these patients. In the present study, however, we demonstrate that the proportion of PAR-2 expressing mucosal mast cells was significantly increased in Crohn's ileitis. These results clearly suggest that the increased number of PAR-2 expressing mast cells in Crohn's ileitis was due to up-regulation in response to local environmental factors in the mucosa, rather than to the increased mast cell number. Moreover, although the sample size of present study did not allow comparisons of PAR-2 labeling intensity between the study groups, a tendency towards a more intense PAR-2 labeling of the mast cells of the Crohn's disease specimens was noted. That is, not only the proportion of PAR-2 labeled mast cells was increased in the Crohn's disease patients, but there also seemed to be increased PAR-2 expression per cell. However, further studies including more patients and the use of methods for quantification of immunofluorescence are needed to verify this possible difference in PAR-2 labeling intensity between Crohn's disease and control specimens. It is not known which factors may modulate PAR-2 expression on mast cells, but inflammatory cytokines have been reported to up-regulate PAR-2 in various cell types. 14, 23, [37] [38] [39] [40] [41] In the present study, we found that TNF-α stimulation up-regulated PAR-2 in the human mast cell line HMC-1. One may speculate, thus, that the up-regulation of PAR-2 on mucosal mast cells in Crohn's ileitis is due to the increased content of inflammatory cytokines in the mucosa, such as TNF-α. 42, 43 Moreover, our finding that PAR-2 was upregulated already in the uninflamed mucosa, suggests that the up-regulation of PAR-2 on mucosal mast cells is a part of the inflammatory process in Crohn's disease. Indeed, increased levels of inflammatory cytokines have been shown even in endoscopically normal tissue in Crohn's disease. 43, 46 However, further studies are needed to clarify which specific factors in addition to TNF-α that are involved in the up-regulation of PAR-2 on mucosal mast cells in Crohns ileitis.
The possible mechanistic role of up-regulation and activation of PAR-2 on mast cells may contribute to the pathophysiology of Crohn's ileitis and needs further study. Tryptase released from activated mast cells may act as a paracrine activator of PAR-2 on target cells, but also as an autocrine and paracrine activator of PAR-2 on the mast cells themselves. 7, 25, 30 It is quite possible that such activation also leads to release of TNF-α from mucosal mast cells. Indeed, most of the TNF-α expressing cells in the human ileal mucosa are mast cells. 33 PAR-2 activation has been shown to increase the release of TNF-α from the HMC-1 cell line, 7, [47] [48] [49] and in the present study we show that TNF-α up-regulates PAR-2 expression. Although this might suggest that TNF-α may upregulate PAR-2 on ileal mucosal mast cells by an autocrine action, this has to be confirmed by further studies involving, for instance, triple immunohistochemical labeling of ileal specimens with antibodies against tryptase, TNF-α and PAR-2. In addition to the paracrine and autocrine activation by tryptase, activation of PAR-2 on mast cells might also be due to the action of other proteases in the intestine, notably trypsin. 1, 10 Crohn's disease is associated with a diminished intestinal epithelial barrier to macromolecules, 46 ,50 and it seems likely, thus, that increased amounts of luminal trypsin may be able to cross the bowel wall in this condition.
In conclusion, our results suggest that PAR-2 is upregulated on ileal mucosal mast cells in Crohn's ileitis, possibly due to the action of inflammatory cytokines, such as TNF-α. Considering that PAR-2 activation on mast cells may result in the release of several inflammatory mediators, one may speculate that up-regulation of PAR-2 on ileal mast cells contributes to perpetuating the inflammatory process in the intestinal mucosa in Crohn's ileitis. Blocking of PAR-2 may thus have therapeutic potential in Crohn's disease.
Finally, we have to emphasize that this is the first study investigating the expression of PAR-2 in Crohn's disease, and that rather few patients were included in the study. Therefore, future studies including a larger number of patients are needed to confirm the present results. Especially the lack of difference in overall PAR-2 expression between Crohn's specimens and control specimens, and in PAR-2 labeling of mast cells between inflamed and uninflamed Crohn's specimens, might have been due to the low number of patients investigated.
